CD19 and B-cell non-Hodgkin lymphoma: First, 12 patients suffering from relapsed/refractory B-cell lymphoma after previous infusion of CD19-specific CAR-T cells received salvage therapy with the anti-PD1 antibody pembrolizumab at a median time of 3.3 months (range, 0.4–42.8 months) from CAR-T-cell infusion [55].